Skip to main content

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Written by Customer Service on . Posted in Public Companies.

BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.

Upcoming Scientific Conferences:

9th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026
Montréal, Quebec

  • Presentation: Ocular Therapeutix: Retina Experience Redefined
    Presentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDT
    Presenter: Peter K. Kaiser, MD, Chief Development Officer
  • Panel Title: The Impact of Recent FDA Guidance on Drug Development
    Panel Date/Time: Tuesday, July 14, 2026, 4:40 – 5:20 PM ET
    Panel Moderator: Pravin U. Dugel, MD, Executive Chairman, President and CEO


The American Society of Retina Specialists (ASRS) 44th Annual Meeting: July 15 – 18, 2026
Montréal, Quebec

  • Presentation: Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results from the Phase 3
    SOL-1 Trial Results
    Session: Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMD
    Presentation Date/Time: Thursday, July 16, 2026, 8:15 – 8:45 AM EDT
    Presenter: Dilsher S. Dhoot, MD
  • Presentation: Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database
    Session: Real-world nAMD: Utilization, Outcomes, and Long-Term Anti-VEGF Data
    Presentation Date/Time: Thursday, July 16, 2026, 8:50 – 8:53 AM EDT
    Presenter: Andrew A. Moshfeghi, MD, MBA, FASRS
  • On-Demand Paper Title: Anti-VEGF Treatment Patterns and Long-Term Vision Outcomes in Patients with nAMD in the IRIS Registry
    Session Date/Time: On-demand papers will be continually available for viewing throughout the meeting
    Presenter: Priya Vakharia, MD
  • Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
    Session: Satellite Symposia
    Symposium Date/Time: Thursday, July 16, 2026, 6:00 – 7:30 PM EDT
    Faculty: Arshad M. Khanani, MD; Dilsher S. Dhoot, MD; Mark R. Barakat, MD; Peter K. Kaiser, MD, Chief Development Officer; and Jeffrey S. Heier, MD, Chief Scientific Officer

Exact medical conference presentation times may be subject to change.

Upcoming Investor Conference:

HC Wainwright 6th Annual Ophthalmology Virtual Conference:
Date: Wednesday, July 22, 2026
Fireside Chat: 4:30 – 5:00 PM EDT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Virtual

A live webcast of the fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.